ACROBiosystems Cell & Gene Tech Expo April 2026: Cell Therapy

The path from CAR construct to clinical-grade cell therapy is rarely linear—and the reagents you choose at each stage can accelerate or derail the entire journey. At Cell & Gene Tech Expo, this presentation explores how integrated reagent strategies bridge the critical gaps between CAR-T and CAR-NK development phases: from early screening and functional characterization through to GMP-compliant expansion. The challenge isn't just finding reagents that work—it's finding reagents that work together, consistently, at scale. Hear how a cohesive reagent framework reduces process variability, supports regulatory expectations, and compresses timelines from discovery to the clinic. Whether you're optimizing constructs in research or preparing for commercial manufacturing, the decisions made at the bench have downstream consequences that matter. Watch this session to understand how smarter reagent integration translates directly into faster, more confident progression of your CAR cell therapy program.

About ACRObiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed to be the cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. ACROBiosystems’ main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.